Wednesday, July 8, 2026

pharma · Idiopathic Pulmonary Fibrosis · Idiopathic pulmonary fibrosis (IPF) · PLRX

PLIANT THERAPEUTICS

Pliant Therapeutics is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker PLRX. Primary therapeutic focus areas include Idiopathic Pulmonary Fibrosis, Idiopathic pulmonary fib

South San Francisco, USA HQ
2015 Founded
122 Employees
Public company Type
PLRX · NYSE Ticker
Company details
Status
Public
HQ
South San Francisco, USA
Founded
2015
Employees
122
Programs
6
Drugs
3
Patents
13
Clinical program

[18F]FP-R01-MG-F2

Phase 1 · small molecule · Idiopathic Pulmonary Fibrosis

[18F]FP-R01-MG-F2 for Idiopathic Pulmonary Fibrosis is a Phase 1 program (small_molecule) at PLIANT THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

← All PLIANT THERAPEUTICS, INC. projects Phase 1 small molecule completed

Internal code IRB Protocol: 40450

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
PLIANT THERAPEUTICS, INC.
Phase
Phase 1
Modality
small_molecule
Indication
Idiopathic Pulmonary Fibrosis
Status
completed
Trials
1

Clinical trials